The Comparative Efficacy of Ceftazidime-Avibactam with or without Aztreonam vs Polymyxins for Carbapenem-resistant Enterobacteriaceae Infections: A Prospective Observational Cohort Study

被引:3
作者
Vijayakumar, M. [1 ]
Selvam, Velmurugan [1 ]
Renuka, M. K. [1 ]
Rajagopalan, Ram Eachambadi [1 ]
机构
[1] Sri Ramachandra Inst Higher Educ & Res, Dept Crit Care Med, Chennai, Tamil Nadu, India
关键词
Aztreonam; Carbapenem-resistant enterobacterales; Carbapenem-resistant enterobacteriaceae; Cohort study; Ceftazidime-avibactam; Colistin; Intensive care unit; Observational study; Polymyxin B; Prospective; COMBINATION THERAPY; COLISTIN; OUTCOMES;
D O I
10.5005/jp-journals-10071-24577
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Carbapenem-resistant enterobacteriaceae (CRE) is associated with high mortality in critically ill patients, with limited treatment options. This study aims to compare clinical response, microbiological response, and mortality in patients treated with ceftazidime-avibactam with or without aztreonam (CAZ-AVI + AZT) and colistin or polymyxin B (polymyxins) in CRE infections. Materials and methods: This single-center prospective observational study included adult patients with CRE infections treated with CAZ-AVI+AZT or polymyxins between January 2022 and December 2022 at a Tertiary Care Medical Center in India. The clinical response, microbiological response, and mortality were compared between the two groups using a Cox multivariate regression model adjusted for the baseline SOFA score and comorbidities. Results: A total of 89 patients were enrolled, with 59 (66%) patients receiving CAZ-AVI + AZT and 30 receiving polymyxins. Baseline demographics and clinical characteristics were similar between the two groups. The Cox multivariate regression analysis showed a statistically significant difference in clinical failure on day 14 with the CAZ-AVI + AZT group vs polymyxins (HR = 0.78, 95% CI 0.63-0.95, p = 0.018). There was no difference in microbiological failure (HR = 1.08, 95% CI 0.66-1.77, p = 0.76), microbiological relapse (HR = 0.75, 95% CI 0.36-3.02, p = 0.62), and hospital mortality (HR = 1.04, 95% CI 0.75-1.43, p = 0.796) between the two groups. Conclusion: Treatment with ceftazidime-avibactam with or without aztreonam for CRE infections associated with a better clinical response compared with polymyxins monotherapy but without any difference in microbiological response or mortality.
引用
收藏
页码:923 / 929
页数:7
相关论文
共 50 条
[41]   Efficacy of Ceftazidime-Avibactam Versus Polymyxin B and Risk Factors Affecting Clinical Outcomes in Patients With Carbapenem-Resistant Klebsiella pneumoniae Infections a Retrospective Study [J].
Fang, Jie ;
Li, Hui ;
Zhang, Min ;
Shi, Guochao ;
Liu, Mengying ;
Wang, Yujie ;
Bian, Xiaolan .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[42]   Efficacy of ceftazidime-avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infections: Focus on solid organ transplantation recipients [J].
Hu, Juan ;
Zha, Lei ;
Yu, Yong-Wei ;
Su, Qun ;
Fang, Xue-Ling ;
Ji, Jin-Ru ;
Shen, Ping ;
Chen, Yun-Bo ;
Zheng, Xia ;
Xiao, Yong-Hong .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (05)
[43]   Ceftazidime/avibactam alone or in combination with an aminoglycoside for treatment of carbapenem-resistant Enterobacterales infections: A retrospective cohort study [J].
Bulman, Zackery P. ;
Cao, Lishan ;
Curry, Brooke N. ;
Biagi, Mark ;
Vivo, Amanda ;
Suda, Katie J. ;
Evans, Charlesnika T. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 64 (05)
[44]   Ceftazidime-Avibactam as Salvage Therapy in Pediatric Liver Transplantation Patients with Infections Caused by Carbapenem-Resistant Enterobacterales [J].
Wang, Weili ;
Wang, Rongrong ;
Zhang, Yuntao ;
Zeng, Lei ;
Kong, Haisen ;
Bai, Xueli ;
Zhang, Wei ;
Liang, Tingbo .
INFECTION AND DRUG RESISTANCE, 2022, 15 :3323-3332
[45]   Ceftazidime-Avibactam as Salvage Treatment for Infections Due to Carbapenem-Resistant Klebsiella pneumoniae in Liver Transplantation Recipients [J].
Chen, Fang ;
Zhong, Han ;
Yang, Tengjiao ;
Shen, Chuan ;
Deng, Yuxiao ;
Han, Longzhi ;
Chen, Xiaosong ;
Zhang, Haomin ;
Qian, Yongbing .
INFECTION AND DRUG RESISTANCE, 2021, 14 :5603-5612
[46]   Clinical Outcomes and Risk Factors for Death in Critically Ill Patients with Carbapenem-Resistant Klebsiella pneumoniae Treated with Ceftazidime-Avibactam: A Retrospective Study [J].
Zhang, Lingchun ;
Ma, Yani ;
Zhao, Chenglong ;
Zhao, Shujuan ;
Zhao, Lulu ;
Yang, Yuxin ;
Wang, Yuhan ;
Meng, Haiyang ;
Sun, Jun .
INFECTION AND DRUG RESISTANCE, 2024, 17 :239-248
[47]   Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed Metallo-β-lactamase production: a systematic review and meta-analysis [J].
Gupta, Nitin ;
Boodman, Carl ;
Prayag, Parikshit ;
Manesh, Abi ;
Kumar, Tirlangi Praveen .
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (04) :203-209
[48]   Ceftazidime-Avibactam Combination Therapy versus Monotherapy for the Treatment Carbapenem-Resistant Gram-Negative Bacterial Infections: A Retrospective Observational Study [J].
Li, Keyang ;
Li, Debao ;
Dong, Hongliang ;
Ren, Dongmei ;
Gong, Dandan ;
Wang, Shubo ;
Li, Yang ;
Wu, Yuanyuan ;
Yang, Jikang ;
Yan, Wenjuan ;
Li, Yi .
INFECTION AND DRUG RESISTANCE, 2024, 17 :1281-1289
[49]   Ceftazidime-Avibactam in Combination with In Vitro Non-susceptible Antimicrobials Versus Ceftazidime-Avibactam in Monotherapy in Critically Ill Patients with Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective Cohort Study [J].
Guanhao Zheng ;
Jianxin Zhang ;
Bei Wang ;
Jiaqi Cai ;
Lili Wang ;
Kaixuan Hou ;
Yan Zhang ;
Liang Zhang ;
Zhitao Yang ;
Juan He ;
Xiaolan Bian .
Infectious Diseases and Therapy, 2021, 10 :1699-1713
[50]   Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae [J].
Haidar, Ghady ;
Clancy, Cornelius J. ;
Chen, Liang ;
Samanta, Palash ;
Shields, Ryan K. ;
Kreiswirth, Barry N. ;
Nguyen, M. Hong .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (09)